Chemical formula: C₇₂H₉₅ClN₁₄O₁₄  Molecular mass: 1,416.09 g/mol  PubChem compound: 16131215

Active ingredient description

Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Abarelix is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L02BX01 Abarelix L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX01

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 183552-38-7
DrugBank Drug: DB00106
KEGG Drug: D02738
PubChem Compound: 16131215
RxNorm Ingredient: 301739
SNOMED-CT Concept: 407128008
Abarelix (substance)
UNII Identifier: W486SJ5824

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.